Event Type
Disclosure
Voluntary
Variant
8-K
. Other Events On October 29, 2025, BridgeBio Pharma, Inc. issued a press release titled “BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Pa
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release titled, “BridgeBio Reports Positive Phase 3 Topline Results for Encalere